Pfizer Inc. closed 16.17% below its 52-week high of $31.54, which the company achieved on July 30th.
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...
However, Pfizer's revenue guidance for 2025 doesn't look particularly exciting. The company expects its top line to come in ...
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $26.44 which represents a slight increase of $0.43 or 1.65% from the prior close of $26.01. The stock opened at $26.01 and touched a low ...
The S&P 500 index has been one of the best-performers of all time. Launched in 1950s when it was trading at $45.4, the ...
An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...
Pfizer Inc. closed 17.53% short of its 52-week high of $31.54, which the company reached on July 30th.
We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...
Ritholtz Wealth Management decreased its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 39.4% during the 4th ...
Viatris has faced volatility since its 2020 formation but is now in Phase 2 of its transformation. Learn why VTRS stock could ...